Last $0.37 USD
Change Today +0.0009 / 0.24%
Volume 456.3K
ONCS On Other Exchanges
Symbol
Exchange
OTC US
Berlin
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

oncosec medical inc (ONCS) Snapshot

Open
$0.38
Previous Close
$0.37
Day High
$0.38
Day Low
$0.36
52 Week High
03/5/14 - $0.97
52 Week Low
02/2/15 - $0.33
Market Cap
92.4M
Average Volume 10 Days
753.3K
EPS TTM
$-0.07
Shares Outstanding
246.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ONCOSEC MEDICAL INC (ONCS)

Related News

No related news articles were found.

oncosec medical inc (ONCS) Related Businessweek News

No Related Businessweek News Found

oncosec medical inc (ONCS) Details

OncoSec Medical Incorporated, a hybrid device and gene therapy biotechnology company, designs, develops, and commercializes medical approaches principally immunotherapy for the treatment of solid tumors in the United States. Its clinical programs include three Phase II clinical trials to assess the ImmunoPulse technology in patients with melanoma, Merkel cell carcinoma, and cutaneous T-cell lymphoma. It has a collaboration agreement with Heat Biologics, Inc. to evaluate the combination of immunotherapy platforms. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated is headquartered in San Diego, California.

42 Employees
Last Reported Date: 10/10/14

oncosec medical inc (ONCS) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $467.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $310.0K
Chief Scientific Officer and Global Head of R...
Total Annual Compensation: $172.8K
Compensation as of Fiscal Year 2014.

oncosec medical inc (ONCS) Key Developments

Heat Biologics, Inc. and OncoSec Medical Inc. Announce Collaboration to Evaluate Combination of Immunotherapy Platforms

Heat Biologics, Inc. and OncoSec Medical Inc. announced that they have entered into an agreement to evaluate the combination of the immunotherapy approaches developed by each company. Under the agreement, Heat and OncoSec will jointly evaluate the preclinical efficacy of Heat's proprietary gp-96-Ig based ImPACT immunotherapy platform using OncoSec's core technology, ImmunoPulse, an investigational stage intratumoral DNA delivery platform. Heat and OncoSec are exploring this combination as part of their ongoing strategy to expand the application of their technologies to benefit cancer patients with unmet medical needs. Heat has two clinical stage programs based on the ImPACT platform, viagenpumatucel-L (HS-110 [2]) in a Phase 2 clinical trial in patients with non-small cell lung cancer and vesigenurtacel-L (HS-410 [3]) in a Phase 2 clinical trial in patients with non-muscle invasive bladder cancer. OncoSec's core platform, ImmunoPulse, which is based on the intratumoral delivery of DNA IL-12, is currently in Phase 2 clinical trials, investigating the approach for treatment of metastatic melanoma, head and neck cancer, triple negative breast cancer, and cutaneous T-cell lymphoma.

OncoSec Medical Incorporated and ARE-SD Region No. 18, LLC Enter into Lease Agreement for Corporate Headquarters and Research and Development Laboratory

On December 31, 2014, OncoSec Medical Incorporated (the Company) and ARE-SD Region No. 18, LLC (the Landlord) entered into a Lease Agreement (the Lease Agreement). Pursuant to the Lease Agreement, the Company has leased certain premises of approximately 33,928 rentable square feet located at 5820 Nancy Ridge Drive, San Diego, California to serve as the company's corporate headquarters and research and development laboratory. The term of the lease agreement is expected to commence on or about October 1, 2015 (the Commencement Date), and expires one hundred twenty (120) months after the Commencement Date.

OncoSec Medical Incorporated Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 09:30 AM

OncoSec Medical Incorporated Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 09:30 AM. Venue: The Waldorf Astoria, New York, New York, United States. Speakers: Punit S. Dhillon, Co-Founder, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONCS:US $0.37 USD +0.0009

ONCS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONCS.
View Industry Companies
 

Industry Analysis

ONCS

Industry Average

Valuation ONCS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOSEC MEDICAL INC, please visit www.oncosec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.